Project Grant R35GM166468
Award Date 8/15/26
Completion Date 3/31/31
Dollars Obligated $418K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The National Institute of General Medical Sciences awarded the University of Pennsylvania $406,250 on March 2, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to advance nucleic acid chemistry and synthetic biology for RNA therapeutics. The research program develops de novo xeno nucleic acids (XNAs)—synthetic nucleic acid analogs with modified backbones that enhance nuclease resistance and extend half-life—to expand the genetic toolkit for RNA silencing and...
- The National Institute of General Medical Sciences awarded The Wistar Institute of Anatomy and Biology $506,550 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on compartmentalization and discrimination of double-stranded RNA in the nucleus. The funded research explores fundamental biological principles governing how cells distinguish self from non-self RNA molecules, specifically examining the balance between sensing pathogenic...
- The National Institute of General Medical Sciences awarded $406,250 to the University of Pennsylvania on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop statistical and computational methods for analyzing complex multimodal biological datasets. The recipient will develop correlated latent factor models to extend multi-omic inference capabilities across complex study designs, including model-based imputation methods for handling missing data...
- The National Institute of General Medical Sciences awarded The Trustees of the University of Pennsylvania $446,875 on April 6, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support a five-year research project on RNA editing and sensing mechanisms in immune regulation. The recipient will investigate how ADAR1-mediated adenosine-to-inosine (A-to-I) RNA editing regulates the labeling of endogenous double-stranded RNA as "self" to prevent unwanted...
- The National Institute of General Medical Sciences awarded $151,352 to the University of Pennsylvania on February 20, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct structural and biochemical characterization of ribosomal RNA methylation by radical SAM enzymes. The project addresses antibiotic resistance mechanisms by examining how two radical S-adenosylmethionine (SAM) enzymes—CFR and RLMN—methylate adenosine residues in bacterial ribosomal RNA. CFR...
- The National Institute of Biomedical Imaging and Bioengineering awarded Vanderbilt University $708,389 on September 3, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to design and implement short interfering RNA (siRNA) conjugates as tools for central nervous system cell-specific gene modulation. The project focuses on developing siRNA conjugates that enable targeted gene knockdown in specific CNS cell types,...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $632,081 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop conformation-sensitive platelet-hitchhiking lipid nanoparticles for targeted delivery of mRNA and small interfering RNA to infarcted heart tissue following myocardial infarction. The project addresses therapeutic limitations in post-infarction recovery by engineering lipid nanoparticles to...
- The National Institute of General Medical Sciences (NIGMS), a component of the National Institutes of Health, awarded The Trustees of the University of Pennsylvania $555,428 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to define the mechanistic underpinnings of AAA+ disaggregases, specifically HSP104 and its partial human homolog SKD3 (human CLPB). The research program seeks to understand at a fundamental level how HSP104 couples ATP...
- The National Institute of Biomedical Imaging and Bioengineering awarded $645,265 to The Trustees of The University of Pennsylvania on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop DNA-loaded lipid nanoparticles (DNA-LNPs) for treating chronic diseases including atherosclerosis and emphysema. The research addresses toxicity barriers that have prevented DNA-LNP development for two decades. Prior...
- The National Institute of General Medical Sciences awarded The Regents of the University of California, San Francisco $445,049 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop membrane-inspired lipid nanoparticles for cell-type-specific expression of programmable RNA. The recipient will design novel lipid nanoparticle formulations to achieve precise, scalable delivery of biomolecules to specific cell types, combining bio-inspired...